AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0

Eleftha 150mg Injection

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Trastuzumab (150mg)

Overview Eleftha 150mg Injection

Oncaspar 150mg Injection treats breast and gastric cancers by targeting and destroying HER2-positive cancer cells. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your individual needs and may vary. Strictly adhere to your prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may not be immediately apparent, requiring several weeks or months; discontinue only under medical supervision. Common side effects encompass nausea, headache, skin rash, sleep disturbances, and increased infection risk. This medication can lower blood cell counts, heightening infection vulnerability, necessitating regular blood tests to monitor blood cell levels, cardiac function, liver health, and uric acid. Report immediately any shortness of breath, cough, chills, or limb swelling. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This injection is contraindicated during pregnancy and lactation; reliable contraception for both partners is crucial throughout treatment.

Primary Ingredients of Eleftha 150mg Injection

No information provided. Please provide the text you wish me to rephrase.

Uses of Eleftha 150mg Injection

Cancers affecting the breast and stomach.

Major Benefits of Eleftha 150mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Eleftha 150mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Eleftha 150mg Injection:

This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.

How Eleftha 150mg Injection works:

Oncaspar, a 150mg injectable monoclonal antibody (IgG1), targets HER2 receptors—proteins driving excessive growth in breast and gastric cancers. By binding to HER2, it directly eliminates cancer cells and concurrently blocks the activation of several oncogenic downstream signaling cascades.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Eleftha 150mg Injection and alcohol may result in pronounced somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Eleftha 150mg Injection during pregnancy poses a confirmed risk to the fetus and is therefore contraindicated. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the inherent dangers. Seek medical advice before use.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administering Eleftha 150mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Eleftha 150mg Injection on driving ability is undetermined. Refrain from driving if any symptoms impairing concentration or reaction time are present.

KidneyKidneySAFE IF PRESCRIBED

For individuals with kidney impairment, the use of Eleftha 150mg Injection appears to pose minimal risk. Current evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Eleftha 150mg Injection to individuals with hepatic impairment. Physician consultation is advised.

What if you forget to take Eleftha 150mg Injection :

Should you forget a scheduled dose of the Eleftha 150mg Injection, seek advice from your physician.

Facts to Know About Eleftha 150mg Injection

LabelValue
Chemical Category Monoclonal antibody
Developing Habits No.
Type of Therapy Cancer Medications
Actions Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Eleftha 150mg Injection

Eleftha 150mg Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bleeding or bruising. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea or vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Effective contraception is recommended for women of childbearing age throughout Eleftha 150mg Injection therapy and for seven months afterward. Pregnancy planning may resume seven months post-treatment.
Treatment with Eleftha 150mg Injection for early breast cancer should continue for one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Eleftha 150mg Injection does not require fasting beforehand. Administration must be supervised by an oncologist and performed only by a qualified healthcare professional.
Eleftha 150mg Injection is available in two formulations: intravenous (IV) infusion and subcutaneous (SC) injection. Always verify the correct formulation is administered as prescribed. The IV formulation is for intravenous use only; it must not be given subcutaneously. Your doctor may change your treatment between the IV and SC formulations as clinically appropriate.
Eleftha 150mg Injection, a monoclonal antibody, targets the HER2 protein found on certain cancer cells. It inhibits cancer growth by binding to HER2. Consequently, this injection is only effective for patients with HER2-positive cancer and is not indicated for those with HER2-negative cancer.
Using Eleftha 150mg Injection with anthracyclines (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and during treatment.
Cardiac evaluations should begin at treatment initiation, continue every three months during treatment, and then every six months post-treatment for up to two years after the final Eleftha 150mg Injection. Patients with pre-existing cardiac conditions require evaluations every twelve weeks.
Eleftha 150mg Injection
6,799